AMICUS THERAPEUTICS, INC.
FOLD evidence brief
What we can confirm
- BioSniper Score:
- 9.3 / 10
- Market Cap:
- $4.55B
- Lead Asset:
- Galafold (Approved)
What it means
What to watch
Prepared research question
What matters most for FOLD—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · FOLD
Amicus Therapeutics, Inc. is a biotechnology company focused on the discovery, development, and commercialization of therapies for rare and orphan diseases.
Key risk: Ongoing Funding Requirements
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Tracking 5 pipeline candidates · 3 FDA decisions for AMICUS THERAPEUTICS, INC..
Amicus Therapeutics, Inc. is a biotechnology company focused on the discovery, development, and commercialization of therapies for rare and orphan diseases.
- As of December 31, 2025, the company reported $217.3 million in cash and equivalents, $185.2 million in total revenue, and a net income of $1.7 million [sec].
- Total debt was reported at $392.7 million as of December 31, 2025 [sec].
- The company's commercial portfolio includes Pombiliti™ + Opfolda™ for the treatment of Pompe disease, which has received regulatory approvals in markets including Spain [sec].
- Amicus continues to advance its pipeline, including research into Fabry disease gene therapy and other novel technologies [sec].
Risks & what to watch (2)›
Key risks
- Ongoing Funding Requirements — The company expects to continue incurring significant costs for R&D and clinical trials [sec_mda].
- Clinical and Manufacturing Dependencies — Future capital needs depend on clinical trial results and the costs of manufacturing drug supplies [sec_mda].
What to watch
- Progress and results of clinical trials for current drug candidates [sec_mda].
- Manufacturing costs and supply chain management for Pombiliti® [sec_mda].
- Potential future acquisitions or in-licensing of assets to support the rare disease pipeline [sec_mda].
Sources: SEC filings · SEC MD&A · Generated June 27, 2026 · How we verify sources →
Run AMICUS THERAPEUTICS, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available AMICUS THERAPEUTICS, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
Cash runway data unavailable
Financial health data unavailable
Lead: Approved
5 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
297
Total value held
$4.57B
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 33,879,048 | $489.9M |
| ubs group ag | 15,957,913 | $230.8M |
| vanguard capital management llc | 14,023,557 | $202.8M |
| pentwater capital management lp | 14,000,000 | $202.4M |
| vanguard portfolio management llc | 13,974,932 | $202.1M |
| state street corp | 12,893,897 | $186.4M |
| fil ltd | 12,560,028 | $181.6M |
| goldman sachs group inc | 11,556,008 | $167.1M |
| qube research & technologies ltd | 8,809,340 | $127.4M |
| hbk investments l p | 8,783,448 | $127.0M |
Showing top 10 of 297 institutional holders of AMICUS THERAPEUTICS, INC.. Open the full 13F history after sign-in.
Short Interest
as of Apr 19, 2026- % of float
- 6.8%
- Days to cover
- 5.6
- Shares short
- 21,099,073
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
FOLD short interestGovernance
Frequently asked questions
What is the AI investment thesis for AMICUS THERAPEUTICS, INC.?
Amicus Therapeutics, Inc. is a biotechnology company focused on the discovery, development, and commercialization of therapies for rare and orphan diseases.
What is AMICUS THERAPEUTICS, INC.'s lead drug candidate?
AMICUS THERAPEUTICS, INC.'s most advanced tracked candidate is Galafold (Approved) for Fabry disease (treatment of adults with a confirmed diagnosis of Fabry disease and an amenable GLA variant; approved in some jurisdictions for adolescents 16 years and older, and in some jurisdictions for adolescents 12 years and older weighing 45 kg or more).
Who is the CEO of AMICUS THERAPEUTICS, INC.?
Mr. Bradley L. Campbell M.B.A. is the chief executive officer of AMICUS THERAPEUTICS, INC. (FOLD).
Where is AMICUS THERAPEUTICS, INC. headquartered?
AMICUS THERAPEUTICS, INC. (FOLD) is headquartered in Princeton, NJ, United States.
What therapeutic areas does AMICUS THERAPEUTICS, INC. focus on?
AMICUS THERAPEUTICS, INC. develops therapies across Rare Disease, Immunology, Dermatology, Nephrology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.